hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma
Circular RNAs (circRNAs) play important roles in the occurrence and development of cancer and chemoresistance. DNA damage repair contributes to the proliferation of cancer cells and resistance to chemotherapy-... (Source: Molecular Cancer)
Source: Molecular Cancer - December 4, 2023 Category: Cancer & Oncology Authors: Lei Xu, Xiao Ma, Xiuzhong Zhang, Chong Zhang, Yi Zhang, Shuai Gong, Nai Wu, Peng Zhang, Xinyu Feng, Jiaxuan Guo, Mengmeng Zhao, Zeqiang Ren and Pengbo Zhang Tags: Research Source Type: research
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia
Pharmacologic targeting of chromatin-associated protein complexes has shown significant responses in KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) but resistance frequently develops to single agents. Th... (Source: Molecular Cancer)
Source: Molecular Cancer - December 4, 2023 Category: Cancer & Oncology Authors: Nuria Tub ío-Santamaría, Ashok Kumar Jayavelu, Tina M. Schnoeder, Theresa Eifert, Chen-Jen Hsu, Florian Perner, Qirui Zhang, Daniela V. Wenge, Fynn M. Hansen, Joanna M. Kirkpatrick, Nidhi Jyotsana, Steven W. Lane, Björn von Eyss, Aniruddha J. Deshpande Tags: Research Source Type: research
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
The molecules of Major histocompatibility class I (MHC-I) load peptides and present them on the cell surface, which provided the immune system with the signal to detect and eliminate the infected or cancerous ... (Source: Molecular Cancer)
Source: Molecular Cancer - December 2, 2023 Category: Cancer & Oncology Authors: Xiangyu Wu, Tianhang Li, Rui Jiang, Xin Yang, Hongqian Guo and Rong Yang Tags: Review Source Type: research
Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients
Immune checkpoint inhibitors (ICIs) are a therapeutic strategy for various cancers although only a subset of patients respond to the therapy. Identifying patients more prone to respond to ICIs may increase the... (Source: Molecular Cancer)
Source: Molecular Cancer - November 30, 2023 Category: Cancer & Oncology Authors: Andrea Sacconi, Paola Muti, Claudio Pulito, Giulia Urbani, Matteo Allegretti, Raul Pellini, Nikolay Mehterov, Uri Ben-David, Sabrina Strano, Paolo Bossi and Giovanni Blandino Tags: Correspondence Source Type: research
The role of extracellular vesicles in circulating tumor cell-mediated distant metastasis
Current research has demonstrated that extracellular vesicles (EVs) and circulating tumor cells (CTCs) are very closely related in the process of distant tumor metastasis. Primary tumors are shed and released ... (Source: Molecular Cancer)
Source: Molecular Cancer - November 30, 2023 Category: Cancer & Oncology Authors: Siyin Guo, Jing Huang, Genpeng Li, Wenjie Chen, Zhihui Li and Jianyong Lei Tags: Review Source Type: research
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state
In this study, we show that... (Source: Molecular Cancer)
Source: Molecular Cancer - November 29, 2023 Category: Cancer & Oncology Authors: Sandra Van Lint, Alexander Van Parys, Bram Van Den Eeckhout, Niels Vandamme, Stephane Plaisance, Annick Verhee, Dominiek Catteeuw, Elke Rogge, Jennifer De Geest, Nele Vanderroost, Jana Roels, Yvan Saeys, Gilles Uz é, Niko Kley, Anje Cauwels and Jan Taver Tags: Research Source Type: research
The University of Kansas Cancer Center (KUCC), an NCI designated comprehensive cancer center
(Source: Molecular Cancer)
Source: Molecular Cancer - November 28, 2023 Category: Cancer & Oncology Authors: Weijing Sun, Natalie Streeter, Joseph McGuirk and Roy Jensen Tags: Editorial Source Type: research
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
The advent of iPSCs has brought about a significant transformation in stem cell research, opening up promising avenues for advancing cancer treatment. The formation of cancer is a multifaceted process influenc... (Source: Molecular Cancer)
Source: Molecular Cancer - November 28, 2023 Category: Cancer & Oncology Authors: Matin Chehelgerdi, Fereshteh Behdarvand Dehkordi, Mohammad Chehelgerdi, Hamidreza Kabiri, Hosein Salehian-Dehkordi, Mohammad Abdolvand, Sharareh Salmanizadeh, Mohsen Rashidi, Anoosha Niazmand, Saba Ahmadi, Sara Feizbakhshan, Saber Kabiri, Nasimeh Vatandoo Tags: Review Source Type: research
Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors
Triple-negative breast cancer (TNBC) is an aggressive subtype that exhibits a high incidence of distant metastases and lacks targeted therapeutic options. Here we explored how the epigenome contributes to matr... (Source: Molecular Cancer)
Source: Molecular Cancer - November 28, 2023 Category: Cancer & Oncology Authors: Pere Llin às-Arias, Miquel Ensenyat-Mendez, Sandra Íñiguez-Muñoz, Javier I. J. Orozco, Betsy Valdez, Matthew P. Salomon, Chikako Matsuba, Maria Solivellas-Pieras, Andrés F. Bedoya-López, Borja Sesé, Anja Mezger, Mattias Ormestad, Fernando Unzueta, Tags: Research Source Type: research
Exploiting innate immunity for cancer immunotherapy
Immunotherapies have revolutionized the treatment paradigms of various types of cancers. However, most of these immunomodulatory strategies focus on harnessing adaptive immunity, mainly by inhibiting immunosup... (Source: Molecular Cancer)
Source: Molecular Cancer - November 27, 2023 Category: Cancer & Oncology Authors: Ming Yi, Tianye Li, Mengke Niu, Qi Mei, Bin Zhao, Qian Chu, Zhijun Dai and Kongming Wu Tags: Review Source Type: research
CDK5: an oncogene or an anti-oncogene: location location location
Recent studies have uncovered various physiological functions of CDK5 in many nonneuronal tissues. Upregulation of CDK5 and/or its activator p35 in neurons promotes healthy neuronal functions, but their overex... (Source: Molecular Cancer)
Source: Molecular Cancer - November 23, 2023 Category: Cancer & Oncology Authors: Kumar Nikhil and Kavita Shah Tags: Review Source Type: research
ELF5 drives angiogenesis suppression though stabilizing WDTC1 in renal cell carcinoma
Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system. Angiogenesis is a main contributing factor for tumorigenesis. E74-like transcription factor 5 (ELF5) has been verified to participa... (Source: Molecular Cancer)
Source: Molecular Cancer - November 18, 2023 Category: Cancer & Oncology Authors: Tushuai Li, Longjiang Xu, Zhe Wei, Shaomei Zhang, Xingyu Liu, Yanzi Yang, Yue Gu and Jie Zhang Tags: Research Source Type: research
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA). (Source: Molecular Cancer)
Source: Molecular Cancer - November 18, 2023 Category: Cancer & Oncology Authors: Kazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, Takuya Tsujino, Kazuki Nishimura, Mitsuaki Ishida, Takuo Hayashi, Ayako Ura, Takaya Ohno, Shogo Yamazaki, Keita Nakamori, Shoko Kinoshita, Ryoichi Maenosono, Masahiko Ajiro, Yuki Yoshikawa, Tomoaki Tak Tags: Research Source Type: research
Outsmarting trogocytosis to boost CAR NK/T cell therapy
Chimeric antigen receptor (CAR) NK and T cell therapy are promising immunotherapeutic approaches for the treatment of cancer. However, the efficacy of CAR NK/T cell therapy is often hindered by various factors... (Source: Molecular Cancer)
Source: Molecular Cancer - November 16, 2023 Category: Cancer & Oncology Authors: Faezeh Ramezani, Ahmad Reza Panahi Meymandi, Behnia Akbari, Omid Reza Tamtaji, Hamed Mirzaei, Christine E. Brown and Hamid Reza Mirzaei Tags: Review Source Type: research
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivoluma... (Source: Molecular Cancer)
Source: Molecular Cancer - November 14, 2023 Category: Cancer & Oncology Authors: Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, David Schoenfeld, Amit Mahajan, Frank Hsu & hellip; Tags: Research Source Type: research
